These antagonists have significant potential for attenuating both soft-tissue cancers and the tissue fibrosis that are driven by dysregulated TGF-β signaling, though as with other TGF-β antagonists, strategies to reduce adverse consequences of on-target inhibition in vital tissues such as the heart must be considered (58, 59). The gene discussed is TGFB1; the disease is cancer.